Overview of Salofalk

The "What is Salofalk?" section provides foundational information regarding the medicine's identity, composition, and general purpose, highlighting its specialized pharmaceutical characteristics.

Property	Description
Active Ingredient	Mesalazine (5-aminosalicylic acid)
Form	Oral tablets/capsules/granules and rectal forms (enemas/suppositories)
Pharmacological Class	Aminosalicylates
Common Use	Managing inflammation in the bowel
Origin	Synthetic compound

Salofalk: Definition, Class, and Composition

Salofalk is a single-ingredient pharmaceutical preparation containing the active component Mesalazine, which is also identified chemically as 5-aminosalicylic acid (5-ASA). It belongs to the Aminosalicylate class of drugs, a category specifically used for its targeted anti-inflammatory effects within the gastrointestinal tract. Mesalazine is clinically recognized as the active therapeutic entity, distinguishing it from related prodrugs that require subsequent metabolic activation. Salofalk is typically available as a prescription-only medicine.

The Purpose of Mesalazine: Localized Anti-Inflammatory Action

The fundamental purpose of Salofalk is to deliver a focused, topical anti-inflammatory action directly to the mucosal lining of the bowel. This action aims to settle and control the chronic swelling, redness, and irritation characteristic of bowel inflammation. The mechanism involves modulating the inflammatory response by decreasing the synthesis of substances such as prostaglandins and leukotrienes. 5-aminosalicylic acid is the active ingredient in multiple formulations intended for managing chronic inflammation that affects the bowel. This specialized local activity is central to its general therapeutic benefit in controlling chronic bowel inflammation.

Available Forms: Oral and Rectal Preparations

Salofalk is manufactured in multiple dosage forms, which is essential to ensure Mesalazine is released and concentrated at the exact site of inflammation. These forms include preparations for oral administration (gastro-resistant tablets, modified-release granules, or capsules) and preparations for rectal administration (suppositories and enemas). The drug's specialized oral forms often feature pH-dependent coatings to ensure that release of the active ingredient is strategically delayed until it reaches the targeted lower segments of the intestine, thereby maximizing the local effect.

Regulatory References

Mesalamine: MedlinePlus Drug Information

What side effects are possible with Salofalk?

Official Adverse Reactions and Safety Profile

The safety profile for Salofalk (mesalazine) is formally classified based on the frequency of documented adverse reactions, according to regulatory standards. These possible effects are grouped by the affected System-Organ-Class, spanning several major physiological domains.

Frequency Classification of Adverse Reactions

The most frequently documented events, classified as Common (may affect up to 1 in 10 people), include headaches and disturbances to the Gastrointestinal System such as abdominal pain, nausea, flatulence, and diarrhea. Uncommon reactions may include heart-related effects like increased heart rate (tachycardia) or dermatological issues like urticaria.

Rare and Very Rare events, while infrequent, are documented across major organ systems, including the Hepatobiliary System (e.g., hepatitis and liver enzyme abnormalities) and the Renal and Urinary System (e.g., interstitial nephritis).

Serious Adverse Reactions and Systemic Safety

Official labeling defines several rare events as serious, requiring caution. These include rare, severe hypersensitivity reactions like myocarditis and pericarditis (inflammation of the heart), as well as specific blood disorders (blood dyscrasias) and severe cutaneous adverse reactions like Stevens-Johnson syndrome (SJS). The Mesalazine-Induced Acute Intolerance Syndrome, which can mimic a disease flare-up with bloody diarrhea and fever, is also documented as a serious reaction.

Population-Specific Safety Constraints

The medication is formally contraindicated in cases of severe renal or hepatic impairment. Regular monitoring of kidney function is a required safety measure, advised both before initiating treatment and periodically during long-term therapy. Caution is also noted for use in older adults due to the higher potential for age-related reductions in organ function.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Data

This section details the officially documented signs and required emergency actions for an overdose of Salofalk (mesalazine), based strictly on government regulatory information.

Documented Overdose Manifestations

As mesalazine is chemically related to salicylates, signs of overdose may resemble salicylate toxicity. Officially documented manifestations include nausea, vomiting, and abdominal pain. Central nervous system effects may involve headache, dizziness, confusion, and tinnitus (ringing in the ears). High-dose exposure can also cause changes in breathing, such as tachypnea (fast or shallow breathing).

Severe Outcomes and Required Actions

Severe mesalazine overdose carries the potential for serious systemic complications, including seizures, electrolyte and blood-pH imbalance, and potential damage to the kidneys (renal) and liver (hepatic).

Regulatory guidance explicitly requires immediate medical attention for a suspected overdose. Emergency services must be contacted immediately if the patient has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Management and Monitoring

No specific antidote exists for mesalazine overdose. Treatment is officially defined as symptomatic and supportive. Due to the potential for renal complications, regulatory documents suggest that monitoring of kidney function may be useful, particularly for elderly patients.

Therapeutic Uses of Salofalk

Salofalk is a brand name for mesalamine, a treatment used to help manage the symptoms of specific inflammatory conditions within the bowel. Its primary use is in addressing ulcerative colitis, which involves inflammation and ulcers in the lining of the large intestine and rectum. The medication is prescribed to manage episodes of mild-to-moderate active disease and, importantly, to help maintain remission once symptoms have stabilized.

The therapeutic purpose is to provide relief from disease manifestations, which may include frequent or loose bowel movements, rectal bleeding, and abdominal discomfort. The medication may be used for managing inflammation specific to the rectum (proctitis), the sigmoid colon, and the left side of the colon (left-sided colitis).

Quick Fact: Relief for Mild-to-Moderate Colitis Symptoms

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Salofalk — Official Regulatory Information

Contraindicated Populations

Salofalk must not be used by patients presenting with the following conditions, as these are absolute regulatory prohibitions:

Known or suspected hypersensitivity to Mesalazine, salicylates (e.g., Aspirin), or any of the formulation's excipients.
Severe impairment of renal function (e.g., GFR < 30 mL/min/1.73 m^2) or severe impairment of hepatic function.
Existing gastric or duodenal ulcer (specified for certain oral forms).

Age-Related Eligibility

Age Group	Eligibility Status (Regulatory Wording)
Adults	Eligible under standard labeled conditions.
Children 6 years and older (Oral Forms)	Use is documented and determined individually.
Children below 6 years of age	Not recommended due to very limited experience.
Children below 12 years (Rectal Forms)	Safety and effectiveness not established; use is not recommended.

Conditional Use and Restrictions

Impaired Organ Function: Use is not recommended in patients with non-severe renal impairment and requires caution in non-severe hepatic impairment. Renal function must be evaluated before and during treatment.
Pregnancy and Lactation: Use is conditional and only permitted if the potential benefit outweighs the possible risk. Mesalazine is excreted in breast milk; if the infant develops diarrhea, breastfeeding must be discontinued.
Other Comorbidities: Caution and monitoring are required for patients with pulmonary disease, particularly asthma, and restrictions apply to specific formulations containing excipients like aspartame (for Phenylketonuria).

What should I know about interactions with other medicines?

The official regulatory profile for Mesalazine (the active ingredient in Salofalk) describes documented interaction patterns primarily concerning additive toxicological risk and modification of effects for co-administered medicines. The government drug labels do not classify any specific drug-drug combinations as an absolute contraindication solely based on an interaction risk. The documented interactions fall under categories of enhanced toxicity risk and altered drug efficacy.

Interacting Substance	Officially Documented Interaction Outcome
Thiopurines (Azathioprine, 6-Mercaptopurine)	Enhanced myelosuppressive effects (increased risk of blood disorders). The FDA notes an in vitro TPMT enzyme inhibition mechanism.
Nephrotoxic Agents (including NSAIDs)	Increased risk of renal reactions or nephrotoxicity due to an additive toxic effect.
Coumarin-type Anticoagulants (e.g., Warfarin)	Possible potentiation of the anticoagulant effect, which may increase the risk of gastrointestinal hemorrhage.
Lactulose or similar preparations	Possible reduction of mesalazine release from certain oral forms due to a decrease in the gastrointestinal pH level.

Mesalazine may also cause an increase in the blood glucose-lowering effects of Sulphonylureas. Additionally, the efficacy of other drug classes may be attenuated, including the diuretic effects of Spironolactone and Frusemide, the anti-uric effects of Probenecid and Sulphinpyrazone, and the tuberculostatic effects of Rifampicin. A population-specific note indicates that the increased risk of renal adverse reactions with co-administered nephrotoxic agents is a particular concern in individuals with known or suspected renal impairment. No mandatory timing separation is documented.

Mechanism of Action

Salofalk's active component, mesalamine (5-aminosalicylic acid or 5-ASA), primarily exerts a topical anti-inflammatory effect directly on the epithelial cells of the colon and rectum, engaging multiple pathways to modify localized inflammatory processes.

Modulation of Arachidonic Acid Metabolism

Salofalk acts within domains involving enzyme-mediated signaling by inhibiting key steps in the cyclooxygenase (COX) and lipoxygenase (LOX) pathways. This modification suppresses the synthesis of pro-inflammatory mediators, including prostaglandins and leukotrienes. Restricting the concentration of these mediators contributes to modulating the downstream signaling to limit activation of responsive pathways.

Scavenging of Free Radicals and Antioxidant Effects

The compound engages mechanisms that influence intracellular signaling in response to stress by functioning as a radical scavenger. It directly binds and neutralizes damaging reactive oxygen species (ROS) produced by activated immune cells. Influencing the cellular redox potential to mitigate pathway dysregulation occurs by reducing the concentration of reactive oxygen species within the local microenvironment.

Influence on Immune Cell Signaling Pathways

Salofalk affects systems where specific signaling patterns drive inflammation by interfering with the activation of the Nuclear Factor-kappa B (NF-κB) pathway. Suppressing this signaling sequence results in diminished nuclear translocation and transcriptional activity of the target factor, thereby modifying immune cell function.

Dosage and Administration Information

How to Use Salofalk: Administration Instructions

Salofalk (mesalazine) must be administered strictly according to the instructions, with the specific route and dose depending on the formulation and treatment phase.

Administration Routes and Preparation

Dosage Form	Route	Preparation Rules
Gastro-resistant Tablets	Oral	Swallow whole with sufficient fluid, do not chew or crush. Take at least one hour before meals.
Prolonged-release Granules	Oral	Place sachet contents on tongue and swallow whole with water, do not chew or crush. Take at the same time each day.
Suppositories, Enema, Foam	Rectal	Administer rectally. Suppositories and enemas are often used at bedtime to aid retention.

Dosing and Frequency

Dosing regimens differ for treating active episodes and maintaining remission.

Treatment Phase	Adult/Elderly Daily Dose	Administration Frequency
Acute Ulcerative Colitis	1.5 g to 4.5 g mesalazine daily (Oral); 0.5 g to 4 g mesalazine daily (Rectal)	Oral dose typically in three divided doses (morning, midday, evening). Rectal dose usually once daily.
Maintenance of Remission	1.5 g mesalazine daily (Oral), adaptable up to 3.0 g daily	Once daily (e.g., as a single dose in the morning) or in divided doses.

Specific Procedural Guidelines

Age-Specific Rules: Children aged 6 years and older require weight-based dosing for oral forms (e.g., 30 mg/kg/day to 50 mg/kg/day for acute treatment). Dosing for adults and the elderly is standardized.

Missed Dose: If a dose is missed, omit it and take the next dose at the regularly scheduled time. Do not take a double dose to compensate.

The medicine must be used regularly and consistently as prescribed, and treatment should not be discontinued abruptly.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Salofalk

Salofalk, which contains the active ingredient Mesalazine, has been the subject of controlled studies and real-world research efforts conducted in patients living with Ulcerative Colitis. The available evidence typically consists of Randomized Controlled Trials (RCTs), where a treatment is compared to a placebo, and longer-term observational studies. This overview describes the research that has been conducted and the outcomes monitored.

Evidence for Managing Active Mild-to-Moderate Ulcerative Colitis

Research scenarios involving periods of increased symptom activity include short-term RCTs. These studies involved adult populations with mild-to-moderate Ulcerative Colitis and monitored outcomes such as Clinical Remission and Endoscopic Remission (healing of the colon lining). Findings describe differences observed in the measured rate of clinical status measurements across these short time frames when compared to placebo groups. Comparative evidence head-to-head between different oral or rectal Mesalazine products is often lacking.

Evidence for Preventing Ulcerative Colitis Relapse (Maintenance)

For long-term management, the evidence is drawn from long-term placebo-controlled trials and observational settings designed to examine the duration of disease stability. Researchers studied for the prevention of relapse in patients whose condition was in a quiescent, or inactive, state. Outcomes related to systemic or functional imbalance were studied, specifically measuring the frequency of relapse and the time until a disease flare-up occurs. Studies provided measurements related to the prevention of relapse when compared to placebo groups over time.

Long-Term Studies and Durability of Response

Observational studies have explored long-term outcomes, following patients for up to several years to track the sustained prevention of conditions involving periods of heightened symptoms. These studies examined how consistent use of Mesalazine was associated with patterns related to long-term outcomes, such as rates of hospitalization. A key challenge highlighted by research is the impact of patient consistency in taking the medication. Data show patterns related to non-adherence, suggesting that inconsistent use of the medicine may be linked to a higher risk of the condition becoming active again.

Evidence in Specific Patient Groups and Disease Locations

Research has explored the use of Mesalazine in certain patient groups, including studies focused on children and adolescents. The measured outcomes in these younger populations were similar to those in adult trials, focusing on achieving clinical status changes. Findings indicate that in these pediatric groups, measured changes in symptoms varied in patterns observed between various oral Mesalazine doses in some short-term treatment settings. Studies also describe how different formulations (oral vs. rectal) were studied to observe outcomes specific to inflammation locations, such as the rectum (proctitis).

Frequently Asked Questions (FAQ)

Common questions about Salofalk (FAQ)

Q: What conditions is Salofalk used for, specifically?

A: Salofalk contains mesalazine, and official regulatory documents state that its primary use is for the treatment of active episodes and the maintenance of remission in Ulcerative Colitis. Some prescribing information also includes use for managing Crohn’s ileo-colitis.

Q: Why do doctors prescribe Salofalk for inflammatory bowel disease?

A: The medicine is designed to work where the inflammation is located. Official labeling indicates the product delivers a focused, topical anti-inflammatory action directly to the lining of the bowel. This action helps settle the chronic swelling and irritation that are characteristic of inflammatory bowel diseases.

Q: How quickly does Salofalk start to work after starting treatment?

A: The time it takes for the medicine to achieve its effect can vary among individuals. In clinical studies, a treatment period of around 8 weeks is often involved for managing acute episodes of ulcerative colitis. The full duration of treatment is determined by a healthcare professional.

Q: Is Salofalk a long-term treatment or short-term?

A: According to official product information, Salofalk is used in two phases: short-term for treating acute episodes (which often lasts several weeks), and long-term for the maintenance of remission. Many patients continue consistent use of the medicine for maintenance to help prevent flare-ups.

Q: Can Salofalk cause stomach pain or upset?

A: Yes, common side effects are those that may affect up to 1 in 10 people. Regulatory documents classify disturbances to the Gastrointestinal System, such as abdominal pain, nausea, flatulence, and diarrhea, as Common adverse reactions.

Q: Are headaches a common side effect reported with Salofalk?

A: Yes, official safety information classifies headaches as a Common adverse reaction. This means headaches are among the effects most frequently reported in association with the medicine.

Q: Is there a risk of kidney issues while taking Salofalk?

A: Renal reactions and deterioration of kidney function, including rare cases of interstitial nephritis, have been reported. Regulatory guidance describes regular monitoring of kidney function as a required safety measure, both before starting treatment and periodically during long-term therapy.

Q: Can women who are planning pregnancy use Salofalk?

A: Official documents state that the use of mesalazine is conditional during the period of planning a pregnancy. The medicine is only permitted if the potential benefit of treatment is judged to outweigh the possible risk to the developing baby. Consultation with a healthcare provider is noted in regulatory information for women who are planning to become pregnant.

Q: Can men using Salofalk still father children?

A: Regulatory information indicates that animal studies on mesalazine show no effect on male fertility. However, oligospermia (a reversible reduction in sperm count) has been reported very rarely among men treated with mesalazine.

Q: What is the main difference between Salofalk tablets and Salofalk granules?

A: The tablets and granules primarily differ in their administration methods (tablets are swallowed whole with fluid, granules are placed on the tongue and swallowed whole). Both forms are designed with specialized coatings or structures to ensure the active ingredient is delivered to the lower segments of the intestine, though their specific release profiles can vary.

Q: Can Salofalk make skin more sensitive to the sun?

A: Official labeling notes that patients with pre-existing skin conditions, such as atopic dermatitis, may need to limit sun exposure. This is due to the potential for more severe photosensitivity reactions (increased sensitivity to sunlight) while taking mesalazine.

Q: What foods or drinks should be avoided while taking Salofalk?

A: Official instructions for the oral tablet form specify that it should be taken at least one hour before meals. Regulatory documents also note that the concurrent use of Lactulose or similar stool-pH-lowering preparations may reduce the intended release of the medicine. No other general dietary or food restrictions are typically documented.

Q: Can Salofalk make you feel tired or dizzy?

A: Official safety data lists adverse effects on the central nervous system and general disorders. Dizziness and a feeling of fatigue or malaise are mentioned as Uncommon or Rare adverse effects in some labels, meaning they are infrequently reported by patients.

Q: How does Salofalk compare generally to other 5-ASA medications?

A: Salofalk is one of several brand-name products containing the active ingredient mesalazine (5-ASA). The main way these different products vary is in their unique formulation—such as specialized coatings or matrices—which are designed to release the active ingredient in a specific area of the gut.

Q: Does Salofalk help prevent flare-ups of inflammatory bowel disease?

A: Yes, the medicine is formally indicated in regulatory documents for the maintenance of remission in ulcerative colitis. This is a therapeutic use specifically designed to help prevent the reoccurrence of disease activity, known as a relapse or flare-up.

Q: Is it normal to see tablet residue in the stool after taking Salofalk?

A: Some mesalazine formulations are specifically designed with coatings to delay the release of the drug until it reaches the lower bowel. With certain products, the occasional observation of a solid, tablet-like residue, sometimes referred to as a 'ghost tablet,' in the stool has been reported.

Q: What happens if I stop taking Salofalk suddenly?

A: Official instructions state that treatment should be consistent and should not be discontinued abruptly. Studies indicate that inconsistent use of mesalazine is linked to a higher risk of the underlying condition becoming active again (a relapse).

Q: Are there different brand names that contain the same ingredient as Salofalk?

A: Yes, the active ingredient in Salofalk is mesalazine (also known as 5-ASA). This compound is available under several other brand names across various countries.

Q: Is Salofalk absorbed into the bloodstream or does it mostly stay in the gut?

A: The medicine's main benefit comes from its topical effect—meaning it works on the surface of the bowel lining. The systemic absorption of the drug into the bloodstream is designed to be limited, allowing most of the medicine to stay in the gut for local anti-inflammatory action.

Q: Is Salofalk safe to take during breastfeeding?

A: Use during breastfeeding is conditional and should only occur if the potential benefit for the mother outweighs the possible risks to the infant. Mesalazine is known to be excreted in breast milk, and if the infant develops diarrhea, regulatory documents note that breastfeeding may need to be discontinued.

Q: Does the time of day matter when taking Salofalk?

A: It is generally recommended to take the medicine at the same time each day to ensure consistent levels of the drug are delivered to the site of inflammation. Specific forms or dosing schedules may require taking doses multiple times a day (e.g., morning, midday, and evening).

Q: Why is it important to have regular blood tests while on Salofalk?

A: Official guidelines describe that regular monitoring is required before and periodically during treatment due to the risk of rare adverse reactions in major organ systems. Blood tests are used to assess the function of the renal (kidney) and hepatic (liver) systems, as well as checking blood cell counts.

How should Salofalk be stored and disposed of?

The required storage conditions for Salofalk (mesalazine) are defined by regulatory agencies to preserve its stability and effectiveness. The instructions vary slightly by formulation:

Temperature: Rectal forms (suppositories, enemas) must generally be stored below 30 C or 25 C, depending on the product, and should not be frozen. Tablets should be kept at controlled room temperature (15 C to 30 C).
Protection: All forms must be protected from light, and products like delayed-release tablets require protection from moisture and excess heat.
Packaging: Keep the medicine in its original package until the time of use.
Child Safety: It is mandatory to keep Salofalk out of the sight and reach of children.
Disposal: Do not dispose of the medicine through wastewater or with household waste. Unused or expired products must be discarded in accordance with local regulations or by consulting a pharmacist for a safe disposal program.

Salofalk